Cost of a human papillomavirus vaccination project, Zimbabwe

• Type of Material: Article
• Authors: Anna Hidle, Centers for Disease Control and Prevention; Gwati Gwati, Government of Zimbabwe; Taiwo Abimbola, Centers for Disease Control and Prevention; Sarah W Pallas, Centers for Disease Control and Prevention; Terri Hyde, Centers for Disease Control and Prevention; Amos Petu, World Health Organization; Deborah McFarland, Emory University; Portia Manangazira, Government of Zimbabwe
• Language: English
• Date: 2018-12-01
• Publisher: World Health Organization (WHO): Creative Commons Attribution
• Publication Version: Final Published Version
• Copyright Statement: © 2018, World Health Organization. All rights reserved.
• License: Creative Commons Attribution 3.0 IGO License
• Final Published Version (URL): http://dx.doi.org/10.2471/BLT.18.211904
• Title of Journal or Parent Work: Bulletin of the World Health Organization
• ISSN: 0042-9686
• Volume: 96
• Issue: 12
• Start Page: 834
• End Page: 842
• Grant/Funding Information: This work was supported by Gavi, The Vaccine Alliance and the United States Centers for Disease Control and Prevention from contract number 200-2015-63464-0001
• Keywords: Life Sciences & Biomedicine; Public, Environmental & Occupational Health; Science & Technology
• Research Categories: Health Sciences, Public Health

Abstract

Objective To determine the cost of Zimbabwe’s human papillomavirus (HPV) vaccination demonstration project. Methods The government of Zimbabwe conducted the project from 2014–2015, delivering two doses of HPV vaccine to 10-year-old girls in two districts. School delivery was the primary vaccination strategy, with health facilities and outreach as secondary strategies. A retrospective cost analysis was conducted from the provider perspective. Financial costs (government expenditure) and economic costs (financial plus the value of existing or donated resources including vaccines) were calculated by activity, per dose and per fully immunized girl. Results The project delivered 11 599 vaccine doses, resulting in 5724 fully immunized girls (5540 at schools, 168 at health facilities and 16 at outreach points). The financial cost for service delivery per fully immunized girl was United States dollars (US$) 5.34 in schools, US$ 34.90 at health facilities and US$ 288.63 at outreach; the economic costs were US$ 17.39, US$ 41.25 and US$ 635.84, respectively. The mean financial cost per dose was US$ 19.76 and per fully immunized girl was US$ 40.03 (economic costs were US$ 45.00 and US$ 91.19, respectively). The largest number of doses delivered (5788) occurred during the second vaccination round (the second group’s first dose concurrently delivered with the first group’s second dose), resulting in the lowest financial and economic service delivery costs per dose: US$ 1.97 and US$ 6.79, respectively. Conclusion The mean service delivery cost was lower in schools (primary strategy) and when more girls were vaccinated in each round, demonstrating scale efficiency.